Breast Cancer: From Pathophysiology to Prevention and Treatment

Dear Colleagues,

Breast cancer continues to be the most commonly diagnosed cancer and the second leading cause of cancer deaths among women. It is subdivided into major subtypes based on the expression of the estrogen receptor (ER) or progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2). Traditionally, treatment strategies are mainly based on the presence or absence of these markers. Lack of these markers defines Triple Negative Breast Cancer (TNBC). However, the recent successes of novel antibody-drug conjugates (ADCs) in breast cancer are changing the biological landscape of breast cancer subtypes and treatment strategies. Furthermore, about a half of HER2-negative breast cancer show lower levels of HER2 expression (HER2-low) that can be candidates for new antibody-drug conjugate treatments. Trastuzumab deruxtecan demonstrates activity not only in HER2-positive, but also in HER2-low breast cancer patients. This Special Issue will discuss the evolving landscape of breast cancer subtypes and focus on our understanding of the pathophysiology, early detection and practice changing treatments in breast cancer.

We aim to stimulate discussion by bringing together expert opinion and new science from across the field in this Special Issue of Cancers. We welcome submissions that cover any relevant topic, including breast cancer subtypes, chemoprevention, prognostic/predictive markers, novel treatment strategies in breast cancer, CDK4/6 inhibitors, novel antibody-drug conjugates (ADCs) for treatment, and immune checkpoint inhibitors.

Dr. Yesim Gokmen-Polar
Prof. Dr. Debra A. Tonetti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.